Your browser doesn't support javascript.
loading
Validating a model for medication-related dental outcomes in older people.
Tan, Edwin C K; Lexomboon, Duangjai; Häbel, Henrike; Fastbom, Johan; Eriksdotter, Maria; Johnell, Kristina; Sandborgh-Englund, Gunilla.
Afiliação
  • Tan ECK; Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.
  • Lexomboon D; Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
  • Häbel H; Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University, Parkville, Vic., Australia.
  • Fastbom J; Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Eriksdotter M; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Johnell K; Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
  • Sandborgh-Englund G; Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.
Oral Dis ; 28(6): 1697-1704, 2022 Sep.
Article em En | MEDLINE | ID: mdl-33780083
ABSTRACT

OBJECTIVES:

To externally validate a model for medication-related dental outcomes in (a) a general older population with dementia and (b) a matched population without dementia. SUBJECTS AND

METHODS:

This validation study used population-based data from seven Swedish national registers (2008-2017). Individuals aged 60+ with dementia were matched to those without dementia on age, gender, and county of residence at the date of diagnosis (index date). The exposure was continuous use of xerogenic medications during the 3-year period before index date. The primary outcome was the number of tooth extraction and restorative procedures within 3 years after index date.

RESULTS:

A total of 334,220 individuals were included in the final sample. In the dementia cohort, the use of urological drugs (incidence rate ratio [IRR] 1.08, 95% CI 1.03-1.13), respiratory medicines (IRR 1.10, 95% CI 1.04-1.17), and proton-pump inhibitors (IRR 1.09, 95% CI 1.05-1.13) was associated with the primary outcome. In the non-dementia cohort, respiratory medicines (IRR 1.03, CI 1.00-1.05), proton-pump inhibitors (IRR 1.06, CI 1.04-1.08), opioids (IRR 1.05, CI 1.03-1.07), and antidepressants (IRR 1.06, CI 1.04-1.08) were associated with the primary outcome.

CONCLUSIONS:

Although there were differences in prescription patterns, the model performed similarly in both those with and without dementia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Bomba de Prótons Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Oral Dis Assunto da revista: ODONTOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Bomba de Prótons Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Oral Dis Assunto da revista: ODONTOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália